^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
engineered autologous T cells
i
Other names: engineered autologous T cells, autologous chimeric T lymphocytes targeted to prostate-specific membrane antigen (PSMA)
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Memorial Sloan-Kettering Cancer Center
Drug class:
PSMA-targeted CAR-T immunotherapy
Related drugs:
5ms
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) (clinicaltrials.gov)
P1, N=13, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
Trial completion date • Trial primary completion date
|
cyclophosphamide • engineered autologous T cells
over1year
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) (clinicaltrials.gov)
P1, N=13, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
Trial completion date • Trial primary completion date • Metastases
|
cyclophosphamide • engineered autologous T cells
over2years
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) (clinicaltrials.gov)
P1, N=13, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
Trial completion date • Trial primary completion date • Metastases
|
cyclophosphamide • engineered autologous T cells
Share via
